US Patent Issued to Genexine on July 1 for "Formulation of modified interleukin-7 fusion protein" (South Korean Inventors)

ALEXANDRIA, Va., July 3 -- United States Patent no. 12,344,647, issued on July 1, was assigned to Genexine Inc. (Seongnam-si, South Korea).

"Formulation of modified interleukin-7 fusion protein" was invented by Donghoon Choi (Seongnam-si, South Korea), Changyong Eun (Seoul, South Korea), Seong Hoon Jeong (Goyang-si, South Korea) and Jun Yeul Lim (Busan, South Korea).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided is a pharmaceutical formulation comprising a modified IL-7 protein. More particularly, it comprises (a) a modified IL-7 fusion protein; (b) a basal buffer with a concentration of 10 to 50 mM; (c) a sugar with a concentration of 2.5 to 5 w/v %; and (d) a surfactant with a concentration of 0.05...